BTIG analyst Sean Lavin upgraded Medtronic to Buy with a price target of $100, saying the recent sell-off in the stock presents an attractive entry point on a "compelling relative valuation". The analyst notes that the company's recent beats have been impressive, but he had been concerned over the difficult expected comps for the second half of the year. Lavin adds that with the "new CVG concerns and cautionary language around tax proposals", Medtronic stock has become especially attractive, especially given his expectation of "results in upcoming quarters, paclitaxel concerns easing, tax changes not materializing, and enthusiasm around low-risk expansion".